Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cordlife GroupCLIFF 42 EV-to-EBITDA is 1.04 as of Jul. 24, 2026, which is 81% below its 10-year median of 5.56. GuruFocus rates CLIFF with a GF Score™ of 42/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Cordlife Group ranks better than 96.58% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cordlife Group's enterprise value is $-5.47 Mil.
Cordlife Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.24 Mil. Therefore, Cordlife Group's EV-to-EBITDA for today is 1.04.
The historical rank and industry rank for Cordlife Group's EV-to-EBITDA or its related term are showing as below:
CLIFF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -334.77 Med: 5.56 Max: 1078.39
Current: 1.16
During the past 13 years, the highest EV-to-EBITDA of Cordlife Group was 1078.39. The lowest was -334.77. And the median was 5.56.
CLIFF's EV-to-EBITDA is ranked better than 96.58% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.61
vs CLIFF: 1.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Cordlife Group (OTCPK:CLIFF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cordlife Group's PE Ratio (TTM) for today is calculated as:
Cordlife Group's share price for today is $0.15048.
Cordlife Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.039.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cordlife Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cordlife Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cordlife Group's EV-to-EBITDA falls into.
Cordlife Group's current Enterprise Value is $-5.47 Mil.
Cordlife Group's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (CLIFF) has a EV-to-EBITDA of 1.04 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cordlife Group. This is 81% below median its historical median of 5.56. According to the industry distribution chart, Cordlife Group ranks #4 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 3.4%.
Is Cordlife Group's EV-to-EBITDA too high?
Cordlife Group's current EV-to-EBITDA of 1.04 is 81% below median its 10-year median of 5.56. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.61. Cordlife Group's value of 1.04 is 92.9% below this industry median. Based on the distribution chart, Cordlife Group ranks #4 out of 117 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cordlife Group has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #4 out of 117 companies for EV-to-EBITDA. This places Cordlife Group in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.61. Cordlife Group's value of 1.04 is 92.9% below this benchmark. While the company's 10-year median is 5.56 vs. the industry median of 14.61, Cordlife Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.61, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current EV-to-EBITDA of 1.04 is 92.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cordlife Group. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current EV-to-EBITDA is 1.04, which is 81% below median its own 10-year median of 5.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current EV-to-EBITDA is 1.04, which is 81% below median its 10-year median of 5.56 and 92.9% below the Medical Diagnostics & Research industry median of 14.61. Cordlife Group's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current EV-to-EBITDA is 1.04 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued.
The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
EV-to-EBITDA: 1.04 (81% below median its 10-year median of 5.56)
GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
Industry Position: 92.9% below the Medical Diagnostics & Research median (#4 of 117)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
42GF Score
Get the complete analysis for CLIFF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
